RESEARCH ARTICLE

REVISED Detection of antifungal drug-resistant and *ERG11* gene mutations among clinical isolates of *Candida* species isolated from Khartoum, Sudan. [version 2; peer review: 2 approved, 1 not approved]

Ahmed Osman Mohamed ^{1,2}, Malik Suliman Mohamed ^{3,4},
Mohamed Abdelrahman Hussain ¹, Ibrahim Fatahalrahman Ahmed⁵

¹Department of Pharmaceutical Microbiology, Faculty of Pharmacy, International University of Africa., Khartoum, 11111, Sudan

²Department of Pharmaceutics, Faculty of Pharmacy, Sudan International University, Khartoum, 11111, Sudan

³Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Al Jouf, P.O.Box 2014, Saudi Arabia

⁴Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum., Khartoum, P. O. Box 1996, Sudan

⁵Department of Microbiology, Faculty of Pure and Applied Science, International University of Africa., Khartoum, 11111, Sudan

V2 First published: 26 Aug 2020, 9:1050
<https://doi.org/10.12688/f1000research.24854.1>

Latest published: 29 Jan 2021, 9:1050
<https://doi.org/10.12688/f1000research.24854.2>

Abstract

Background: *Candida* species are one of the most important opportunistic fungal pathogens that cause both superficial and systemic infections, especially in immunocompromised individuals. Considering the sharp increase in the rate of *Candida* infections, and resistance to commonly used antifungal agents in the last decades; this study was conducted to determine the rate of resistance among clinical isolates of *Candida* species, and to characterize some of the resistant genes among resistant isolates collected in Khartoum.

Methods: This is a cross-sectional laboratory-based study included 100 pre-screened *Candida* species isolates from Khartoum state hospitals. Chromogenic media was used for *Candida* isolation and/or identification. The standard disc diffusion method was performed to investigate the susceptibility to fluconazole, itraconazole, and amphotericin. Following genomic DNA extraction, the entire *ERG11* gene was amplified from some *C. albicans* resistant isolates, sequenced, and further analyzed.

Results: Out of 100 clinical isolates collected, 51% were *C. albicans*, followed by *C. glabrata* (31%), *C. krusei* (8%), *C. tropicalis* (5%), and *C. dubliniensis* (5%). Resistance rate was 23% for fluconazole, 4% for itraconazole, while there were no amphotericin resistant isolates detected. *C. albicans* *ERG11* gene sequence reveals 15 different mutations. Among these, three (D116E, E266D, and V488I) were missense mutations; however, these substitutions do not contribute to fluconazole resistance.

Open Peer Review

Approval Status

	1	2	3
version 2 (revision) 29 Jan 2021			 view
version 1 26 Aug 2020	 view	 view	
1. Rasoul Mohammadi , Isfahan University of Medical Sciences, Isfahan, Iran 2. Raja Ahsan Aftab , Taylor's University, Subang Jaya, Malaysia 3. Muhammad Sajid Hamid Akash , Government College University, Faisalabad, Pakistan			
Any reports and responses or comments on the article can be found at the end of the article.			

Conclusion: *C. albicans* was found to be the most common species. Resistance against fluconazole was observed most frequently; however, mutations in *ERG11* are unlikely to be the reason behind fluconazole resistance among these isolates.

Keywords

Candida species, fluconazole resistance, ERG11

This article is included in the **Pathogens** gateway.

This article is included in the **Cell & Molecular Biology** gateway.

This article is included in the **Antimicrobial Resistance** collection.

Corresponding author: Ahmed Osman Mohamed (ahmedkunna93@hotmail.com)

Author roles: **Osman Mohamed A:** Conceptualization, Funding Acquisition, Writing – Original Draft Preparation; **Suliman Mohamed M:** Conceptualization, Supervision, Validation, Writing – Review & Editing; **Abdelrahman Hussain M:** Methodology, Software, Writing – Review & Editing; **Fatahalrahman Ahmed I:** Methodology, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Osman Mohamed A *et al.* This is an open access article distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Osman Mohamed A, Suliman Mohamed M, Abdelrahman Hussain M and Fatahalrahman Ahmed I. **Detection of antifungal drug-resistant and *ERG11* gene mutations among clinical isolates of *Candida* species isolated from Khartoum, Sudan.** [version 2; peer review: 2 approved, 1 not approved] F1000Research 2021, 9:1050 <https://doi.org/10.12688/f1000research.24854.2>

First published: 26 Aug 2020, 9:1050 <https://doi.org/10.12688/f1000research.24854.1>

REVISED Amendments from Version 1

In this new version we have added statement in the last paragraph of the Introduction explaining rational behind selecting this three antifungal (fluconazole, itraconazole, and amphotericin).

additionally in Result section, we have provided the percentage of resistance with respect to gender (in the first paragraph of results) and frequency and percentage of resistance in relation to site of isolation.

Moreover, we have added new set of comparisons in the Discussion (third paragraph), to highlight about the regional resistance, compare, give possible reasons, and provide future recommendation. By including more studies from Egypt, Ethiopia, Ghana, Burkina Faso, India, and Nigeria.

Any further responses from the reviewers can be found at the end of the article

Introduction

The genus *Candida* is a dimorphic opportunistic fungal pathogen that colonizes the vagina, gastrointestinal and mucosal oral cavity of immunocompetent individuals. In contrast, critically ill and/or immunocompromised patients frequently develop *Candida* infection that range from superficial to systemic infections¹. *Candida* comprises over 150 species, of which 17 are prevalent and known to infect humans; these include *Candida albicans*, *Candida glabrata*, *Candida parapsilosis*, *Candida tropicalis*, and *Candida krusei*^{2,3}.

Since the 1980s, there has been a steady increase in the incidence and prevalence of serious secondary systemic fungal infections⁴. The risk factors for developing systemic or superficial *Candida* infections include intensive care unit admissions, HIV infection, organ transplantation, cancer and anticancer drugs, diabetes mellitus and other demographic factors such as age and sex⁵⁻⁹.

Various antifungals are used for treatment of *Candida* infections, among them, azoles which showed good activity and are relatively safe, however, resistance to this group is occurring more frequently¹⁰. On the other hand, resistance of *Candida* species against other antifungals such as Polyenes, Echinocandins, and Allylamines has not been reported extensively¹¹.

There are different molecular mechanisms through which eukaryotic cells may develop drug resistance such as alteration in efflux pump, alteration in intracellular drug processing i.e. modification or degradation, alterations in the target enzyme and/ or other enzymes. Among these mechanisms, alteration of the targeted enzyme and alteration of efflux pump are the most common in *Candida* species¹².

Alteration in the target enzyme

The azoles bind to and inhibit the activity of 14 α -demethylase, a key enzyme in the fungal ergosterol synthesis pathway, which belongs to the cytochrome P450 family¹⁰. One of the known potential resistance mechanism of azoles is alteration in the

ergosterol syntheses pathway. *Candida* species can develop resistance by mutation/s in the gene (*ERG11*) which codes for the enzyme 14 α -demethylase¹³. The point mutation in the *ERG11* gene can result in an amino acid substitution which in turn produces a conformational change in the enzyme and decreases the affinity to azoles, however, susceptibilities are not affected equally by different mutations as the presence of some mutations such as Y132H, R467K, and I471T confirm resistance, on the other hand, mutations such as E266D does not affect the resistance¹⁴. In addition, drug resistance might develop through overexpression of the *ERG11* gene through increased mRNA level which might increase the concentration of the enzyme in comparison to sensitive isolates¹⁵.

Efflux pump

Efflux pumps are the basic mechanism in most eukaryotic cells by which unwanted toxic materials are forced out of the cell. Two types of efflux pumps have been identified: ATP binding cassette (ABC) transporters and major facilitator superfamily (MFS)¹⁶. ABC transporters are pumps that are actively associated with the efflux of potentially toxic molecules to the cell, and they are primarily hydrophobic and lipophilic¹⁷. Many different pumps are known to belong to the different families, such as *Candida* resistance (*CDR1&2*) genes that are related to the PDR5 family, and known to be associated with resistance to antifungals¹⁵. The MFS pumps work by anti-proton power i.e. proton pumped inside the cell and hydrophobic and/or lipophilic material pumped outside the cell. This is coded by multidrug resistance gene (MDR1) which found to be overexpressed in fluconazole resistant isolates, however, the gene was not overexpressed in other azoles, ketoconazole and itraconazole, resistant strains¹⁸. Some authors have tried to link overexpression of CDR1, 2 and MDR1, concluding that deletions of these genes will result in more susceptible isolate than each gene alone¹².

Among different antifungals, Fluconazole was the most commonly prescribed, amphotericin and itraconazole remains to be the cornerstone in the management of systemic fungal infections in Sudan since echinocandins are not yet registered (Sudan National Essential Medicine List- 2014)¹⁹. Due to the scarcity of reports about the rate of drug resistance and resistant genes among *Candida* species in the study area, this study was conducted to screen the susceptibility of different *Candida* species towards commonly used antifungals, and to identify the role of *ERG11* gene mutation/s in the development of fluconazole resistance. To this end, we collected and identified isolates of *Candida* species, selected the most resistant isolates, amplified and sequenced the conserved domain of the *ERG11* gene and detected the impact of the mutation(s) on the enzyme 14 α -demethylase's structure and function using *in silico* tools^{20,21}.

Methods

Ethical statement

This study was reviewed and approved by the Research ethical committee, Faculty of Medicine & Health Science, International University of Africa (IUA) (6-2017). Oral informed consent was obtained from the participating patients, when

their hospital laboratory result was positive for *Candida* species. Oral consent was obtained over written consent (where it was recorded), since the majority of the patients included in this study were illiterate (in case of minors, consent was obtained from parents or guardians). The structure of the consent was approved by the Research Ethics Committee.

Study design, area and participants

This was a cross-sectional laboratory-based study using clinical isolates of *Candida* species. Clinical isolates were collected from different Khartoum state hospitals in a period between September 2017 to September 2018, all clinical isolates primarily identified as *Candida* species regardless of age, gender, and site of isolations, were included. Samples and demographic data were obtained directly from the patients within each hospital after consent was obtained by the principle investigators.

Sample size calculation

Sample size was calculated using the following formula on cross-sectional studies²²:

$$n = Z^2 * P (1-P) / d^2$$

Where, n = desired sample size, Z = critical value and a standard value for the corresponding level of confidence (1.96), P = expected frequency of resistance obtained from previous studies (7%)^{23,24}, d = margin of error (0.05).

$$n = 1.96^2 * 0.07 (1-0.07) / (0.05)^2 = 100 \text{ samples.}$$

Sample collection and storage

A total of 100 clinical isolates of *Candida* species were collected from Khartoum state hospitals, Sudan. The isolates were pre-identified at each hospital's laboratory using conventional methods such as wet mount, gram stain, germ tube, and growth on Sabouraud Dextrose Agar media (SDA). Immediately after collection, the isolates were grown into SDA (M063, HIMEDIA, Mumbai, India) at 32°C for 24–48 hours. From the grown culture, colonies were picked and streaked over a slant of SDA in screw-cap tubes, each slant was filled with sterile liquid glycerol and tightly closed and stored in 4 °C until recovered.

Identification

Chromogenic media Hi-Chrome *Candida* differential agar media supplemented with chloramphenicol 0.5g/L (M1297A, HIMEDIA, Mumbai, India) was used to differentiate between *Candida* species based on colonies' color and morphology. A subculture from the stock culture was allowed to grow on SDA for 24 hour, subsequently one well isolated colony from the grown culture was picked out and streaked over the prepared Hi-Chrome media and incubated at 32°C for 24–48 hours, the result was interpreted as per manufacture instructions (*C. albicans*—light green, *C. glabrata*—cream to white, *Candida krusei*—pale, fuzzy and *C. tropicalis*—blue to purple, *C. dupeyris*—pale green)²⁵.

Antimicrobial sensitivity testing

Sensitivity testing to all isolated *Candida* species was carried out as recommended by the Clinical Laboratories and Standard

Institute (CLSI)²⁶. A modified Mueller Hinton Agar media (M173, HIMEDIA, Mumbai, India) supplemented with 2% glucose and methyl blue 5µg/mL was used. Using overnight culture on SDA, the inoculum was prepared by suspending 4 well-isolated colonies in 5mL sterile saline, inoculum size was adjusted by matching the turbidity with standard McFarland which was prepared by adding 0.5 mL BaCl₂ (0.048 mol/L) to 99.5 mL H₂SO₄. Within 15 minutes after adjusting the turbidity and by using sterile cotton swab, the microorganisms were streaked from the center of the petri dish to the top, each time the plate was rotated 60° to ensure that the agar surface is at least double streaked. Within 15 minutes after streaking, three discs, namely fluconazole 25µg, itraconazole 10µg and amphotericin 10µg (SD232, SD221, SD111. HIMEDIA, Mumbai, India) were applied to each inoculated petri dish, gently pressed into the agar using sterile forceps, incubated at 32°C for 24–48 hours, zone diameter around each disc were measured using calipers and result was interpreted as per CLSI²⁶.

Genomic DNA extraction, gene amplification, detection and sequencing

Genomic DNA was extracted using guanidine chloride method, briefly, DNA extraction was carried out using 48 hours grown culture on SDA media, three to five colonies were washed with 5 mL phosphate buffer saline (PBS) three times, then 2 mL white cell lysis buffer and 20 µL of proteinase K (10 mg/mL; iNtRON Inc, Korea) were added to the pellet in a Falcon tube, vortexed and incubated at 37°C overnight. Then 1 mL from guanidine chloride (7M; iNtRON Inc, Korea) and 350 µL of ammonium acetate (7M; Loba Chemie, India) were added. The tubes were vortexed and incubated at 65°C in a water bath for 2 hours. After that 2 mL pre chilled chloroform (sd Fine-Chem limited, India) was added, and centrifuged at 6000 RPM for 20 minutes and the supernatant was transferred into a new Falcon tube and completed to 10 mL volume with pre chilled absolute ethanol (Carlo Erba, France) and incubated overnight at -20°C for completion of DNA precipitation. After incubation the tubes were centrifuged at 6000 RPM for 20 minutes, then the ethanol was poured off and the same step was repeated with 70% ethanol. After that the tubes were left to air dry. Finally, DNA was suspended in 80 µL TE buffer (iNtRON Inc, Korea) and incubated at 4 °C until used²⁷, as a template for PCR. The *ERG11* gene from *C. albicans* was amplified using previously published primers^{14,28}: forward: (5'-CAAGAAGATCATAACTCAAT-3') and reverse (3'-AGAACACTGATCGAAAG-5') (Macrogen Inc. Korea). All PCRs were carried out in final volume of 20 µL containing *Maxime* PCR PreMix Kit *i-Tag* (2.5U *i-Tag*™ DNA polymerase, 2.5mM each dNTPs, 1x reaction buffer and 1x Gel loading buffer), 1µL each forward and reverse primer (10pmol final concentration), 2.5µL genomic DNA, and the volume was completed with distilled water. The PCR was carried out in G-storm thermocycler with the following conditions: initial denaturation at 94°C for 4 min; 35 cycle of denaturation at 95°C for 30 s, primer annealing at 55°C for 30 s, and extension at 70°C for one min; followed by final extension step at 72°C for 10 min. The final product was visualized by loading 3µL in 0.8% agarose gel electrophoresis for 45 minutes under the voltage 100 V. Distinct bands were observed under UV light and photographed. The *ERG11* gene from the most *C. albicans* resistant isolates (isolate 10,

13, and 14) and one sensitive isolate (24 randomly selected, double blinded by independent researcher) were selected for sequencing (Sanger sequencing in BGI, Shenzhen, China). All sequences were deposited in GenBank and accession numbers MT081007, MT081008, MT081009, MT081010 for isolate 10, 13, 14, and 24, respectively, were obtained. Sequences were aligned based on fluconazole susceptible strain SC5314 (GenBank accession number X13296) using **BioEdit** software version 7.2.5.

Results

Collection and identifications

Out of 100 samples collected, 80 were from females and 20 from males with a mean age of 40. 66 isolates were from urine samples, 17 from sputum, 12 were high from vaginal swabs, and 5 from other sites. Overall, the most common species was *C. albicans* (n=51), while the most prevalent Non-*albicans* species was *C. glabrata* (n=31), followed by *C. krusei* (n=8). **Table 1** provides a detailed description on the frequency of each species with respect to the site of isolation²⁹.

Antifungal sensitivity testing (AST)

Fluconazole was the least effective agent followed by itraconazole. Itraconazole resistance was observed among Non-*C. albicans* (NCA) species, high frequency of intermediate susceptibility dose-dependent (ISDD) was observed for itraconazole among all *Candida* species, while there was no amphotericin resistant isolate detected. Rate of resistance among female isolates 28.75% (23 out of 80) was higher than the male 15% (3 out of 20).

Fluconazole resistance was observed in 23% of *C. albicans* samples, only 2 isolates were ISDD, and the remaining isolates (72.5%) were sensitive, there were no itraconazole and amphotericin resistant *C. albicans* isolates. However, 31% were categorized as ISDD to itraconazole. Among NCA species, 19.4% of *C. glabrata* were fluconazole resistant, as well as all *C. krusei* isolates (8). Azole cross resistance was observed among

2 *C. glabrata* and 2 *C. krusei* isolates. One *C. dupeyensis* was resistant to fluconazole while there were no *C. tropicalis* resistant isolates. Complete AST results are shown in **Table 2**²⁹.

C. albicans *ERG11*'s gene amplification, electrophoresis analysis and sequencing

The complete *ERG11* gene coding region (1587 bp) from *C. albicans* resistant isolates (12) and one sensitive isolate (control) were amplified as shown in **Figure 1**³⁰. Sequence analysis revealed 15 different mutations, 12 of which were silent, and 3 were non-synonyms **Table 3**. T495A and G1609A were observed only in resistant isolates (isolate 10 and 14 respectively), while A945C was observed in sensitive and resistant isolates (isolate 13, 14, and 24). All mutations were previously reported (**Table 3**³¹).

Discussion

In the current study, 100 clinical isolates of different *Candida* species were collected, identified, and their susceptibilities to fluconazole, itraconazole, and amphotericin were determined. The *ERG11* gene was amplified from some resistant isolates to investigate the impact of different mutations in the enzyme activity and hence drug susceptibility.

Nearly half of the samples collected were *C. albicans* (51%), while *C. glabrata* (31%) and *C. krusei* (8%) being the most prevalent of the other species identified (**Table 1**²⁹). *C. albicans* remains to be the most common species (51%), a similar finding was obtained in Sudan, in 2008, in a study that aimed to characterize vaginal candidiasis among pregnant woman indicating that the prevalence was 81%³². More recently in 2018 a study conducted on cancer patients at the Isotope and Radiation Center in Sudan, concluded that the prevalence of *C. albicans* was 59%³³, however, these numbers indicate that the prevalence of non-*Candida albicans* species are increasing: 19% in 2008, 41% in 2018, and 49% in this study. This result indicates the necessity of culturing any suspected *Candida* infections at species level for proper management.

Table 1. Different site of isolations in relation to frequency of each *Candida* species identified.

Specimens	<i>Candida</i> species					Total	Overall rate of resistance
	<i>C. albicans</i>	<i>C. glabrata</i>	<i>C. krusei</i>	<i>C. tropicalis</i>	<i>C. dupeyensis</i>		
Urine	34	20	6	3	3	66	(19) 28.78%
Sputum	7	7	0	1	2	17	(3) 17.64%
Vaginal swab	9	1	1	1	0	12	(3) 25%
Throat swab	1	2	0	0	0	3	(0) 0%
Blood	0	0	1	0	0	1	(1) 100%
Catheter	1	0	0	0	0	1	(0) 0%
Total	51	31	8	5	5	100	(26) 26%

Table 2. The sensitivities of different species towards the selected antifungal drugs.

Species	Drug	Category			Total
		Sensitive (%)	Intermediate (%)	Resistant (%)	
<i>C. albicans</i>	F	37 (72.5%)	2 (4%)	12 (23.5%)	51
	I	35 (68.6%)	16 (31.4%)	0%	51
	A	49 (96%)	2 (4%)	0%	51
<i>C. glabrata</i>	F	25 (80.6%)	0%	6 (19.4%)	31
	I	7 (22.5%)	22 (71%)	2 (6.5%)	31
	A	15 (48.3%)	16 (51.7%)	0%	31
<i>C. krusei</i>	F	0%	0%	8 (100%)	8
	I	4 (50%)	2 (25%)	2 (25%)	8
	A	1 (12.5%)	7 (87.5%)	0%	8
<i>C. tropicalis</i>	F	3 (60%)	2 (40%)	0%	5
	I	4 (80%)	1 (20%)	0%	5
	A	5 (100%)	0%	0%	5
<i>C. dubliniensis</i>	F	4 (80%)	0%	1 (20%)	5
	I	2 (40%)	3 (60%)	0%	5
	A	5 (100%)	0%	0%	5

F: Fluconazole, I: Itraconazole, A: Amphotericin.

Figure 1. Agarose gel Electrophoresis showing the bands of amplified *ERG11* gene. From left to right lanes: L, 100 bp DNA ladder, 1 to 12 lanes are the amplified *Candida albicans* *ERG11*'s gene (1587 bp).

Antimicrobial sensitivity testing reveals that fluconazole was the least effective agent, followed by itraconazole, while there were no amphotericin resistant isolates (Table 2^{29,30}). Fluconazole resistance rate was 23%, this finding strictly similar to the finding from Nigeria 24% and India 20%, 19.5%^{34–36}. A higher rate of resistance was reported in Ethiopia 38% and more

recently 2020 in Ghana (48.1%)^{37,38}. On the other hands, a lower resistance rate was reported in Egypt 11%³⁹. Regarding Itraconazole resistance, as few as 4 isolates of *C. krusei* and *C. glabrata* were resistant, this is in contrast to the finding from Ethiopia and Burkina Faso in which itraconazole resistance was as higher as 50 and 52% respectively^{37,40}. This variation

Table 3. Different mutations of ERG11 gene and amino acid substitutions.

Isolates number	Position of mutation	Mutation From - To	Amino acid substitution
Silent mutation (s)			
10, 13, 14, and 24	462	T – C	No
13, 14, and 24	558	C – T	No
13 and 14	696	T – C	No
10, 13, 14, and 24	805	C – T	No
10, 13, 14, and 24	1143	T – C	No
10	1167	A – G	No
13, 14, and 24	1173	A – G	No
10, 13, 14, and 24	1257	C – T	No
13, 14, and 24	1350	T – C	No
13, 14, and 24	1443	C – T	No
10, 13, 14, and 24	1449	T – C	No
10	1587	A – G	No
Non- synonym mutation (s)			
10	495	T – A	Asp 116 Glu
13, 14, and 24	945	A – C	Glu 266 Asp
14	1609	G – A	Val 488 Ile

Asp= Aspartic acid, Glu= Glutamic acid, Val= Valine, Ile= Isoleucine

All sequences were aligned based on *C. albicans* reference strain, with X13296 GenBank accession number.

in susceptibility rate might be attributed to difference in previous exposure to fluconazole since several studies have described that azole resistance is highly associated with previous exposure to fluconazole^{40,41}. Concerning azole cross-resistance, all isolates that were itraconazole resistant were fluconazole resistance, similar finding was obtained previously in which the cross-resistance rate was 83%. Unlike azoles, amphotericin was the most effective agents (100%) a comparable finding was obtained in Egypt (98.7%), Ethiopia (93.7%), India (90%), and Ghana (87.2%)^{35,37–39}. This potent susceptibility profile of amphotericin could be due to it is limited uses.

It has been observed that drug resistant fungal pathogens are increasing, and reduced susceptibility to azoles, especially fluconazole, along with azole cross resistance was detected³. According to these findings we believe that there is urgent need for AST, especially when physicians intend to prescribe fluconazole as it is the least effective agents, or in such settings that non- *C. albicans* species are suspected as they possess relatively high rates of resistance.

The *ERG11* gene was sequenced from some *C. albicans* resistant isolates and one sensitive isolate for the purpose of

examining the impact of different mutations (if present) on fluconazole resistance. The three detected mutations (T495A, A945C, and G1609A, which precipitate D116E, E266D, and V488I aa substitutions respectively) have been described previously in both sensitive and resistant isolates, and strongly suggesting that they are not contributed directly to resistance.

In the present study, E266D aa substitution which was described by some authors as the most common polymorphism in the *ERG11* gene has been detected in both sensitive (isolate 24) and resistant (isolate 13, 14) isolates (Table 3³¹), so our finding completely agree with previous data which concluded that this mutation alone has no role in resistance^{28,42}.

In our analysis, D116E and V488I aa substitutions were detected only in resistant isolates (isolate 10 and 14 respectively, Table 3³¹); the same results have been described previously^{28,43}; however, the detection of these mutation in fluconazole susceptible isolates indicates that they lack a vital role in the development of resistance¹⁴. In isolate 14, E266D and V488I were found together, a similar finding was obtained previously⁴³. The impact of E266D occurring simultaneously with other mutations such as K143R, F145L, and G464S have been well characterized using site directed mutagenesis⁴², unlike the coexistence of E266D and V488I which is needed to be more clarified.

One of the limitation in this study is that we are unable to detect some regions and therefore some mutations at the beginning and/or end of the *ERG11* gene because of their low quality (common problem in Sanger sequencing for sequences more than 1000 bp)⁴⁴. We have tried to solve this problem by using either forward or reverse sequencing reads, however, it was very difficult to double check some of these mutations for further confirmations. Our recommendation in this regard is to consider different sequencing techniques that are able to detect the entire region (1587bp) reliably.

According to our results, *ERG11* gene mutations in *C. albicans* was not the main causes of resistance, our future recommendations lay on considering alternative resistance mechanisms, more especially, studying the expression level of *CDR1*, *CDR2*, *MDR1*, and *ERG11* genes which expected to give a complete view of the resistance processes.

Conclusion

Nearly half of the identified isolates were *C. albicans*, and the most prevalent non- *C. albicans* was *C. glabrata*. Among all antifungals tested, fluconazole was the least effective, while all isolates were sensitive to amphotericin. The detected missense mutations were not directly associated with fluconazole resistance; however, resistance among these isolates might be due to other mechanisms such as efflux pump gene overexpression.

Data availability

Underlying data

All sequences were deposited in GenBank under accession numbers MT081007, MT081008, MT081009, and MT081010 for isolate 10, 13, 14, and 24, respectively.

Figshare: demographic, identification, sensitivity test data. <https://doi.org/10.6084/m9.figshare.12449615.v1>²⁹

This project contains the following underlying data:

- sample collection sheet for F1000.xlsx (A spreadsheet contain data regarding patients age, gender and site of isolation, species assay results for each sample coupled with susceptibility to fluconazole, itraconazole and amphotericin).

Figshare: sequence data for ERG11 gene. <https://doi.org/10.6084/m9.figshare.12600128.v1>³¹

This project contains the following underlying data:

- 10__[19070622] F__D01_1907004923G.ab1 (Raw sequence data for opening in Finish TV for isolate 10, forward sequencing).
- 10__[19070624]R__A02_1907004923G.ab1 (Raw sequence data for opening in Finish TV for isolate 10, reverse sequencing).
- 13__[19070622]F__E01_1907004924G.ab1 (Raw sequence data for opening in Finish TV for isolate 13, forward sequencing).
- 13__[19070624]R__B02_1907004924G.ab1 (Raw sequence data for opening in Finish TV for isolate 13, reverse sequencing).
- 14__[19070622]F__F01_1907004925G.ab1 (Raw sequence data for opening in Finish TV for isolate 14, forward sequencing).
- 14__[19070624]R__C02_1907004925G.ab1 (Raw sequence data for opening in Finish TV for isolate 14, reverse sequencing).
- 24__[19070622]F__G01_1907004926G.ab1 (Raw sequence data for opening in Finish TV for isolate 24, forward sequencing).
- 24__[19070622]F__G01_1907004926G.ab1 (Raw sequence data for opening in Finish TV for isolate 24, reverse sequencing).

Figshare: candida identification using Hi-chrome media and gel electrophoresis for ERG11 gene. <https://doi.org/10.6084/m9.figshare.12775769.v1>³⁰

This project contains the following underlying data:

- ERG11 gene from C. albicans.jpg (Raw image for PCR gel for ERG11 gene).
- 131733_2018.3.7.jpg (Raw images for identification of isolates 1-9, inverted plate).
- 131739_2018.3.7.jpg (Raw images for identification of isolates 1-9, upright plate).
- 131718_2018.3.7.jpg (Raw images for identification of isolates 15-22, inverted plate).
- 131724_2018.3.7.jpg (Raw images for identification of isolates 15-22, upright plate).
- 131630_2018.3.7.jpg (Raw images for identification of isolates 27-34, upright plate).
- 131637_2018.3.7.jpg (Raw images for identification of isolates 27-34, inverted plate).
- 131532_2018.3.7.jpg (Raw images for identification of isolates 45-52, inverted plate).
- 131541_2018.3.7.jpg (Raw images for identification of isolates 45-52, upright plate).
- 131555_2018.3.7.jpg (Raw images for identification of isolates 56-63, upright plate).
- 131605_2018.3.7.jpg (Raw images for identification of isolates 56-63, inverted plate).
- 131619_2018.3.7.jpg (Raw images for identification of isolates 64-71, upright plate).
- 131645_2018.3.7.jpg (Raw images for identification of isolates 64-71, inverted plate).
- 131659_2018.3.7.jpg (Raw images for identification of isolates 73-80, inverted plate).
- 131708_2018.3.7.jpg (Raw images for identification of isolates 73-80, upright plate).
- 131508_2018.3.7.jpg (Raw images for identification of isolates 82-86, upright plate).

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

References

1. Sardi J, Scorzoni L, Bernardi T, et al.: **Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options.** *J Med Microbiol.* 2013; **62**(Pt 1): 10–24. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Lass-Flörl C: **The changing face of epidemiology of invasive fungal disease in Europe.** *Mycoses.* 2009; **52**(3): 197–205. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Szweda P, Gucwa K, Romanowska E, et al.: **Mechanisms of azole resistance among clinical isolates of Candida glabrata in Poland.** *J Med Microbiol.* 2015; **64**(6): 610–9. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Yoon HJ, Choi HY, Kim YK, et al.: **Prevalence of fungal infections using National Health Insurance data from 2009–2013, South Korea.** *Epidemiol Health.* 2014; **36**: e2014017. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Sah P, Patel P, Chandrashekar C, et al.: **Oral candidal carriage correlates with**

- CD4⁺ cell count but not with HIV and highly active antiretroviral therapy status.** *J Invest Clin Dent.* 2019; **10**(4): e12438.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Koehler P, Stecher M, Cornely OA, *et al.*: **Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis.** *Clin Microbiol Infect.* 2019; **25**(10): 1200–1212.
[PubMed Abstract](#) | [Publisher Full Text](#)
 7. Chouhan S, Kallianpur S, Prabhu KT, *et al.*: **Candidal prevalence in diabetics and its species identification.** *Int J Appl Basic Med Res.* 2019; **9**(1): 49–54.
[PubMed Abstract](#) | [Free Full Text](#)
 8. Kim YJ, Kim SI, Choi JY, *et al.*: **Invasive fungal infection in liver transplant recipients in a prophylactic era: A multicenter retrospective cohort study in Korea.** *Medicine (Baltimore).* 2019; **98**(26): e16179.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 9. Pfaller M, Diekema D: **Epidemiology of invasive candidiasis: a persistent public health problem.** *Clin Microbiol Rev.* 2007; **20**(1): 133–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 10. Allen D, Wilson D, Drew R, *et al.*: **Azole antifungals: 35 years of invasive fungal infection management.** *Expert Rev Anti Infect Ther.* 2015; **13**(6): 787–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
 11. Bossche HV, Marichal P, Odds FC: **Molecular mechanisms of drug resistance in fungi.** *Trends Microbiol.* 1994; **2**(10): 393–400.
[PubMed Abstract](#) | [Publisher Full Text](#)
 12. White TC, Marr KA, Bowden RA: **Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.** *Clin Microbiol Rev.* 1998; **11**(2): 382–402.
[PubMed Abstract](#) | [Free Full Text](#)
 13. Spettel K, Barousch W, Makristathis A, *et al.*: **Analysis of antifungal resistance genes in *Candida albicans* and *Candida glabrata* using next generation sequencing.** *PLoS One.* 2019; **14**(1): e0210397.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 14. Ying Y, Zhao Y, Hu X, *et al.*: **In vitro fluconazole susceptibility of 1,903 clinical isolates of *Candida albicans* and the identification of ERG11 mutations.** *Microb Drug Resist.* 2013; **19**(4): 266–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 15. Chen L, Xu Y, Zhou C, *et al.*: **Overexpression of CDR1 and CDR2 genes plays an important role in fluconazole resistance in *Candida albicans* with G487T and T916C mutations.** *J Int Med Res.* 2010; **38**(2): 536–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 16. Jia XM, Ma ZP, Jia Y, *et al.*: **RTA2, a novel gene involved in azole resistance in *Candida albicans*.** *Biochem Biophys Res Commun.* 2008; **373**(4): 631–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Prasad R, De Wergifosse P, Goffeau A, *et al.*: **Molecular cloning and characterization of a novel gene of *Candida albicans*, CDR1, conferring multiple resistance to drugs and antifungals.** *Curr Genet.* 1995; **27**(4): 320–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 18. Marger MD, Saier Jr MH: **A major superfamily of transmembrane facilitators that catalyze uniport, symport and antiport.** *Trends Biochem Sci.* 1993; **18**(1): 13–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Al Balushi KA, Alzaabi MA, Alghafri F: **Prescribing Pattern of Antifungal Medications at a Tertiary Care Hospital in Oman.** *J Clin Diagn Res.* 2016; **10**(12): FC27–FC30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 20. Venselaar H, te Beek TA, Kuipers RK, *et al.*: **Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces.** *BMC Bioinformatics.* 2010; **11**(1): 548.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. Capriotti E, Fariselli P, Casadio R: **I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure.** *Nucleic Acids Res.* 2005; **33**(Web Server issue): W306–W10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Pourhoseingholi MA, Vahedi M, Rahimzadeh M: **Sample size calculation in medical studies.** *Gastroenterol Hepatol Bed Bench.* 2013; **6**(1): 14–7.
[PubMed Abstract](#) | [Free Full Text](#)
 23. Mulu A, Kassu A, Anagaw B, *et al.*: **Frequent detection of 'azole'-resistant *Candida* species among late presenting AIDS patients in northwest Ethiopia.** *BMC Infect Dis.* 2013; **13**(1): 82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Toda M, Williams SR, Berkow EL, *et al.*: **Population-based active surveillance for culture-confirmed candidemia—four sites, United States, 2012–2016.** *MMWR Surveill Summ.* 2019; **68**(8): 1–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. Baradkar VP, Mathur M, Kumar S: **Hichrom candida agar for identification of *Candida* species.** *Indian J Pathol Microbiol.* 2010; **53**(1): 93–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Wayne P: **Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline.** M44-A2 edn, Clinical and Laboratory Standards Institute; 2009.
[Reference Source](#)
 27. Alsadig G, Arbab MA, Aldeaf SA, *et al.*: **Allele frequency of P53 gene Arg72Pro in sudanese meningioma patients and controls.** *J of SCIENTIFIC & TECHNOLOGY RES.* 2014; **3**(6): 2277–8616.
[Reference Source](#)
 28. Wang B, Huang LH, Zhao JX, *et al.*: **ERG11 mutations associated with azole resistance in *Candida albicans* isolates from vulvovaginal candidosis patients.** *Asian Pac J Trop Biomed.* 2015; **5**(11): 909–14.
[Publisher Full Text](#)
 29. Kunna A, Osman A: **demographic, identification, sensitivity test data.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.12449615.v1>
 30. Kunna A: **candida identification using Hi-chrome media and gel electrophoresis for ERG11 gene.** *figshare.* Media. 2020.
<http://www.doi.org/10.6084/m9.figshare.12775769.v1>
 31. Kunna A: **sequence data for ERG11 gene.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.12600128.v1>
 32. Nemery HM: **Phenotypic Characterization of Vaginal Candidiasis in Sudanese Pregnant Women.** *Afr J Med Sci.* 2019; **4**(4).
[Reference Source](#)
 33. Nagla MM, El Fadil OE, Muzamil AHM, *et al.*: **Internal transcribed spacer for identification of yeast species isolated from cancer patients at the Isotope and Radiation Center, Khartoum, Sudan: A cross-sectional, case-control study [version 1; peer review: 1 approved, 1 approved with reservations].** *F1000Res.* 2018; **7**: 443.
[Publisher Full Text](#)
 34. Damen JG, Cosmas EU, Daminabo VM: **Prevalence and antifungal susceptibility profile of Vulvovaginal candidiasis amongst women of reproductive age in Jos Metropolis, Nigeria.** 2017.
[Reference Source](#)
 35. Khadka S, Sherchand JB, Pokhrel BM, *et al.*: **Isolation, speciation and antifungal susceptibility testing of *Candida* isolates from various clinical specimens at a tertiary care hospital, Nepal.** *BMC Res Notes.* 2017; **10**(1): 218.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. ElFeky DS, Gohar NM, El-Seidi EA, *et al.*: **Species identification and antifungal susceptibility pattern of *Candida* isolates in cases of vulvovaginal candidiasis.** *Alexandria J Med.* 2016; **52**(3): 269–77.
[Publisher Full Text](#)
 37. Sasikala G, Agatha D, Janagond A, *et al.*: **Characterization of *Candida* and its antifungal susceptibility pattern from patients with vaginal candidiasis in a tertiary care hospital in South India.** *J Pharm Biomed Sci.* 2013; **30**(30): S1–S6.
 38. Tsega A, Mekonnen F: **Prevalence, risk factors and antifungal susceptibility pattern of *Candida* species among pregnant women at Debre Markos Referral Hospital, Northwest Ethiopia.** *BMC Pregnancy and Childbirth.* 2019; **19**(1): 527.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 39. Waikhom SD, Afeke I, Kwawu GS, *et al.*: **Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of *Candida* isolates.** *BMC Pregnancy Childbirth.* 2020; **20**: 266.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Zida A, Yacouba A, Bamba S, *et al.*: **In vitro susceptibility of *Candida albicans* clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).** *J Mycol Med.* 2017; **27**(4): 469–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Cartledge JD, Midgley J, Gazzard BG: **Clinically significant azole cross-resistance in *Candida* isolates from HIV-positive patients with oral candidosis.** *Aids.* 1997; **11**(15): 1839–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Flowers SA, Colón B, Whaley SG, *et al.*: **Contribution of clinically derived mutations in ERG11 to azole resistance in *Candida albicans*.** *Antimicrob Agents Chemother.* 2015; **59**(1): 450–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Sardari A, Zarrinfar H, Mohammadi R: **Detection of ERG11 point mutations in Iranian fluconazole-resistant *Candida albicans* isolates.** *Curr Med Mycol.* 2019; **5**(1): 7–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 44. Wang XV, Blades N, Ding J, *et al.*: **Estimation of sequencing error rates in short reads.** *BMC Bioinformatics.* 2012; **13**(1): 185.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 11 May 2021

<https://doi.org/10.5256/f1000research.54119.r84350>

© 2021 Akash M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Muhammad Sajid Hamid Akash

Department of Pharmaceutical Chemistry, Government College University, Faisalabad, Pakistan

1) No need for subtitle in the introduction.

2) It will be better if the author could provide more resistance reports for his region in the introduction. Instead of extensively describing unnecessary parts such as the efflux pump as it is not covered in the study methodology.

3) The most important finding must be stated in the first most paragraph of the discussion.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pharmaceutical Analysis

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 11 November 2020

<https://doi.org/10.5256/f1000research.27422.r73504>

© 2020 Aftab R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Raja Ahsan Aftab

¹ Faculty of Health and Medical Sciences, School of Pharmacy, Taylor's University, Subang Jaya, Malaysia

² Faculty of Health and Medical Sciences, School of Pharmacy, Taylor's University, Subang Jaya, Malaysia

The study is about anti-fungal sensitivity testing and detection of resistant gene/s. It is important to carry out such kinds of studies to help prescribers and policymakers in making better future plans and guidelines for the treatment of candida infection.

- It would be better if the authors could clarify why these 3 anti-fungal drugs were selected for the sensitivity testing in the introduction.
- The authors need to add a few more studies and comparisons about the candida resistance during the discussion.
- The authors collected 100 samples from different sites and genders, the exact percentage of resistance/sensitive isolates with regard to gender and site of isolation can be added to the tables or as a text.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical Pharmacy , infectious disease , nephrology , treatment outcomes

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 25 Jan 2021

Ahmed Kunna

Dear Prof Raja Ahsan Aftab:

Thank you for your valuable comments.

In response to your 3 comments we have:

1. Justified the reasons for selecting the 3 antifungals in the Introduction.
2. We have added the percentage of resistant isolates in relation to gender in Result section, and the percentage of each site of isolations as crosstabulation in Table 1.
3. We have comprehensively discussed the pattern of antifungal resistance especially in our region (Africa) in the Discussion section by adding 7 additional citations.

Competing Interests: No competing interests were disclosed

Reviewer Report 07 September 2020

<https://doi.org/10.5256/f1000research.27422.r70299>

© 2020 Mohammadi R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rasoul Mohammadi

¹ Department of Medical Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

² Department of Medical Parasitology and Mycology, School of Medicine, Isfahan University of

Medical Sciences, Isfahan, Iran

This manuscript is a common epidemiological study. It has some major drawbacks including:

1. Isolates were identified by phenotypic methods. Genus of *Candida* contains about 200 species and identification needs to confirm by molecular techniques. Conventional methods are not enough to identify *Candida* spp.
2. The majority of isolates were obtained from urine and sputum (66+17). *Candida* spp. are normal flora and authors have to confirm the infections caused by these fungi.

Isolation of *Candida* from urine (candiduria) is not an infection, we have some criteria for urinary tract infections (UTIs), and the authors have to confirm it.

Isolation of *Candida* from sputum is not important because we can isolate *Candida* spp. from sputum, even in immunocompetent individuals.

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

No

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

No

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Medical Mycology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 27 Jan 2021

Ahmed Kunna

Dear Prof Rasoul Mohammadi;

Thank you for comprehensively reviewing our paper and for your appreciated comments:
Regarding the first comments;

The primary objective of the study was to isolate the medically important *Candida* species, characterizing *Candida* at species level is beyond the scope of the study. The sensitivity and specificity of Chromogenic media in differentiating as well as isolating common species such as (*C. albicans*, *C. glabrata*, *C. Krusie*, and *C. tropicals*) is well documented in the previous studies (see *Evaluation of chromogenic media and seminested PCR in the identification of Candida species*), according to previous publication in Sudan; more than 90% of infections due to *Candida* species was caused by this species (see *Internal transcribed spacer for identification of yeast species isolated from cancer patients at the Isotope and Radiation Center, Khartoum, Sudan: A cross-sectional, case-control study*). On the other hand, culturing was the efficient and the easiest way to isolate the mixed isolates within the same sample.

With respect to the second comments;

Candiduria is considered one of the most controversial issues in patient management. As well as isolation of *Candida* from oral cavity since this species is a commensal microbe. During the course of sample collections (1 year), we have tried to overcome this problem by carefully selecting our isolates for eligibility since:

1. All of isolates were derived from a patient with some risk factors such as *Diabetes mellitus*, hospitalised patient, and elderly patients.
2. All isolates were recovered from patients with characteristic sign and symptoms for UTI, while the growth of bacteria was insufficient to prove bacterial infections. In most of the cases urine analysis as well as culture were repeated.
3. The final decision of considering *Candida* as a sole causative agent was made by a physician, upon that recommendations sample were considered eligible.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research